A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Active Lupus Nephritis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Belimumab (Primary) ; Azathioprine; Cyclophosphamide; Mycophenolate; Steroids
- Indications Lupus nephritis
- Focus Therapeutic Use
- Acronyms BLISS-LN
- Sponsors GlaxoSmithKline; Human Genome Sciences
- 20 Oct 2017 Planned End Date changed from 7 Feb 2020 to 5 Feb 2020.
- 20 Oct 2017 Planned primary completion date changed from 26 Jul 2019 to 24 Jul 2019.
- 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.